Lifeboat Foundation

Today, we have an interview with Dr. Nichola Conlon, one of the speakers at the Undoing Aging 2018 Conference in Berlin, hosted by the Forever Healthy Foundation and SENS Research Foundation.

Introducing Nuchido

Dr. Conlon is the CEO of Nuchido, a new company that is set to launch later this year and was encouraged in part by four recent breakthroughs in biogerontology, which each showed rejuvenation in mammals [1–9]. These studies, which were all published in leading peer-reviewed scientific journals, showed that rejuvenation of aged animals was possible via different mechanisms of action.

A human study of the mitochondrial antioxidant MitoQ shows promise in addressing some aspects of vascular aging.

Antioxidant-based therapeutics to forestall the effects of aging have had a long history, ever since the elaboration of the free radical theory of aging by Denham Harmon in 1956. However, this long history has also had mixed results, with studies alternately showing efficacy, a lack of efficacy, or even negative health effects for some applications of antioxidants. Many of these studies analyzed the results of taking high doses of naturally occurring antioxidants. In general, high doses are necessary due to the poor bioavailability of many of these naturally occurring compounds.

The poor bioavailability of Coenzyme Q10, a naturally occurring antioxidant that is found in cells and decreases with age, spurred scientists to develop a synthetic form. This form, dubbed MitoQ, is very similar in structure to the naturally occurring form, only it has a triphenylphosphonium moiety that allows this derivative to be two to three orders of magnitude more permeable to membranes, particularly the membranes of mitochondria. It is within mitochondria that MitoQ appears to be doing most of its work by soaking up reactive molecules, generated as byproducts of respiration, that can oxidize and damage lipids and proteins.

Continue reading “Antioxidant MitoQ Combats Vascular Aging in Human Study” »

We are delighted to announce our first US conference in NYC. An action-packed day of research and investment and the first of the events we have planned this year.

At the Frederick P. Rose Auditorium, Cooper Union in New York City, we will be hosting a special one-day conference focused on aging research and biotech investment. Developing therapies from initial concepts, through clinical testing, and ultimately to market takes a pipeline, and right now, that pipeline is being built to support the next step in medicine: rejuvenation biotechnology. Join us for this exciting event, where industry experts will be sharing their insights on the advances and investment prospects in an industry poised to revolutionize medicine forever.

Sometimes, people laugh imagining themselves as elderly people. Would they laugh imagining themselves as diseased?

If you watched a TV show, or read a comic book, where the difficulties and suffering of an oncological patient were portrayed in a disrespectful, humorous way, you would likely be outraged; at the very least, you would think that the show or comic book was in seriously bad taste. You’d probably think the same about similar material involving a disabled person or anyone who, because of an incurable disease, had only a short time to live spent in increasing misery—for example, a child affected by progeria, a disease that may best be described as a sort of accelerated aging syndrome that kills off its victims in their mid-twenties at the very latest.

Yet, it is not uncommon to see the diseases of old age, and even elderly people in general, being laughed at in just such a way without causing much outrage at all. Why is there a difference?

Continue reading “Aging is no laughing matter” »

As April ends and, at least in the Northern Hemisphere, summer approaches, let’s have a look at the progress of worldwide efforts to extend the summer of life.

Kazan 2018: Interventions to Extend Healthspan and Lifespan

The highlight of April was unquestionably the Interventions to Extend Healthspan and Lifespan Conference, which was held in Kazan, Russia on April 23–26. Featuring over 40 distinguished speakers from the field of aging research, this conference, which was the fifth in the series, included talks on epigenetics, genomics, metabolomics, aging biomarkers, bioinformatics, effective advocacy, and more. LEAF board director Elena Milova attended the event and had the chance to interview several of the experts present, such as Dr. Andrei Gudkov and Professor David Gems. We will publish more interviews of these speakers in the coming weeks, so stay tuned!

Elena Milova was at the Interventions to extend healthspan and lifespan 2018 conference in Kazan this week. This is an important conference in the aging research field, and it includes a variety of leading experts giving talks about their research. During the event, Elena had the opportunity to talk with professor David Gems about his work and his views on aging.

Professor Gems is a British geneticist and biogerontologist. He is Professor of Biology of Ageing at University College London, where he is also Deputy Director of the Institute of Healthy Ageing. His work focuses on understanding aging through the genetics of the nematode worm C. elegans.

https://www.uqpower.com.au/podcast/spotlight-on-ira-pastor-genetic-regeneration

But that’s not the only reason robots are big here. It also has a lot to do with an aging and declining population.

“Japan is a strange, exotic and quirky place” — but that’s not the only reason it’s on the leading edge of a robot revolution.